About the Study
The Glycemia Reduction Approaches in Diabetes: A Comparative
Effectiveness Study (GRADE) is a long-term study of different
treatments for type 2 diabetes.
GRADE is funded by the National Institute of Diabetes and Digestive and
Kidney Diseases, part of the National Institutes of Health (NIH). Type 2
diabetes is an epidemic that threatens to become the century's major public health problem and poses enormous human and economic challenges worldwide. Most people with diabetes eventually need 2 medications to control blood glucose levels. A major challenge is to determine which of the many possible drugs is the best choice among people already treated with
metformin, the most commonly used diabetes drug.
GRADE is a randomized clinical trial of participants diagnosed with type 2
diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to 1 of 4 commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years. The goal of the GRADE Study is to
determine which combination of two diabetes medications is best for achieving good glycemic control, has the fewest side effects, and is the most beneficial for overall health in long-term treatment for people with type 2 diabetes.
44 clinical sites in the United States are currently recruting and enrolling
participants. The study plans to enroll 5,000 participants, and follow them up to 7 years. Please see the "Participating Centers" map to view the locations and
local contact information of the GRADE clinical sites.
Recruitment is underway at all 44 clinical sites throughout the country, and more than 1,460 participants have been
randomized into GRADE. (3/1/2015)
For More Information
The GRADE Coordinating Center is located at The
| || |
| || |
GRADE study members should contact the GRADE webmaster with any problems logging on or accessing documents from the website.